EWTX
Edgewise Therapeutics, Inc.
Set alert
38.90 USD -0.01 -0.03%
38.02 Day range 39.44
17.09 52-week range 48.35
- YTD
- +56.73%
- 1 year
- +108.36%
- Open
- 38.72
- Prev close
- 38.91
- Mkt cap
- 4.22B
- Vol
- 967.63K
- Avg vol
- 1.46M
- EPS
- -1.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 38.02
- High
- 39.44
- Forward P/E
- -21.93
- Beta
- 0.35
- Short ratio
- 6.61
- Inst. own
- 112.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 41.43
- 200-d avg
- 36.22
- 1y target
- 52.62
Key statistics
- Market cap
- 4.22B
- Enterprise value
- 3.77B
- Trailing P/E
- 0.00
- Forward P/E
- -21.93
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.36
- EPS (TTM)
- -1.86
- Beta
- 0.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -92.31M
- Total cash
- 460.71M
- Total debt
- 3.59M
- Return on equity
- -38.03%
- Shares outstanding
- 108.60M
- Short % of float
- 15.25%
- 50-day average
- 41.43
- 200-day average
- 36.22
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 52.62 +35.3% upside
Now 38.90
- Target (low)
- 36.00
- Target (mean)
- 52.62
- Target (high)
- 66.00
Ratings (0m) 14 12 buy · 2 hold · 0 sell
- Strong buy3
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 2.51.
Financials — quick view
EWTX Revenue — quarterly 0
EWTX Net income — quarterly -57.33M
EWTX EPS — quarterly -0.53
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.53198 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.46769 | -0.53 | -0.06 | -13.32% |
| May 7, 2026 | Mar 31, 2026 | -0.50 | -0.46 | +0.04 | +8.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.43 | -0.47 | -0.04 | -9.30% |
| Nov 6, 2025 | Sep 30, 2025 | -0.40 | -0.39 | +0.01 | +2.50% |
| Aug 7, 2025 | Jun 30, 2025 | -0.42 | -0.34 | +0.08 | +19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Sep 21, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 20, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 11, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 20, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Jul 9, 2026 | Oppenheimer | init | — | Outperform |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- edgewisetx.com
News
- William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
- Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
- Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
- Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
- Biotech Options Buzz: UTHR, NMRA, EWTX
- 91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Your note
Sign in to keep a note on EWTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARRUTHERS ROBERT MICHAEL | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 11, 2025 | 86,162 |
| DERAKHSHAN BEHRAD | Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 31,826 |
| DONOVAN JOANNE M | Officer | Sale | Aug 12, 2026 | 8,625 |
| EDRIS BADREDDIN | Director | Conversion of Exercise of derivative security | Jan 20, 2026 | 19,820 |
| FOX JONATHAN C | Director | Stock Award(Grant) | Jun 30, 2026 | 24,833 |
| KOCH KEVIN | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 52,488 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 14.29% | 15,518,492 | 603.67M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 9.41% | 10,215,455 | 397.38M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.73% | 8,392,730 | 326.48M | Jun 29, 2026 |
| Blackrock Inc. | 6.08% | 6,606,336 | 256.99M | Jun 29, 2026 |
| Jupiter Topco LLC | 5.59% | 6,075,331 | 236.33M | Jun 29, 2026 |
| FMR, LLC | 5.05% | 5,489,135 | 213.53M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 2,902,230 | 112.90M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.71% | 1,855,091 | 72.16M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.42% | 1,542,890 | 60.02M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.80% | 864,638 | 33.63M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.79% | 856,214 | 33.31M | Jul 30, 2026 |
| Victory Portfolios IV-Victory Pioneer Select Mid Cap Growth Fund | 0.73% | 794,393 | 30.90M | Aug 30, 2026 |